Amedisys (AMED) Stock Forecast, Price & News

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 2 sell ratings, 6 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares.
View AMED analyst ratings or view top-rated stocks.

15 equities research analysts have issued 12 month target prices for Amedisys' stock. Their AMED share price forecasts range from $81.00 to $165.00. On average, they predict the company's stock price to reach $108.94 in the next twelve months. This suggests a possible upside of 40.9% from the stock's current price.
View analysts price targets for AMED or view top-rated stocks among Wall Street analysts.

Amedisys' stock was trading at $83.54 at the beginning of 2023. Since then, AMED stock has decreased by 7.5% and is now trading at $77.31.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023.
View our AMED earnings forecast.

Amedisys, Inc. (NASDAQ:AMED) announced its quarterly earnings results on Thursday, May, 4th. The health services provider reported $1.00 EPS for the quarter, topping analysts' consensus estimates of $0.86 by $0.14. The health services provider earned $556.39 million during the quarter, compared to analyst estimates of $558.98 million. Amedisys had a trailing twelve-month return on equity of 14.35% and a net margin of 5.02%. The business's revenue for the quarter was up 2.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.23 earnings per share.

ETFs with the largest weight of Amedisys (NASDAQ:AMED) stock in their portfolio include Harbor Health Care ETF (MEDI), Simplify Health Care ETF (PINK), SPDR S&P Health Care Services ETF (XHS), First Trust Health Care AlphaDEX Fund (FXH), SRH U.S. Quality ETF (SRHQ), Distillate Small/Mid Cash Flow ETF (DSMC), iShares U.S. Healthcare Providers ETF (IHF) and BlackRock Future Health ETF (BMED).

Amedisys declared that its board has initiated a stock buyback program on Wednesday, August 4th 2021, which authorizes the company to buyback $100,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 1.2% of its stock through open market purchases. Stock buyback programs are often a sign that the company's leadership believes its stock is undervalued.

Amedisys issued an update on its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share guidance of $4.14-$4.36 for the period, compared to the consensus earnings per share estimate of $4.25. The company issued revenue guidance of $2.25 billion-$2.27 billion, compared to the consensus revenue estimate of $2.26 billion.

478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD).

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Amedisys' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.33%), Wellington Management Group LLP (7.98%), JPMorgan Chase & Co. (6.13%), Riverbridge Partners LLC (4.69%), Mackenzie Financial Corp (3.20%) and State Street Corp (2.83%). Insiders that own company stock include Bruce D Perkins, Bruce D Perkins, Christopher Gerard, David L Kemmerly, David L Kemmerly, Denise M Bohnert, Michael Paul North, Richard A Lechleiter, Scott G Ginn and Sharon Brunecz.
View institutional ownership trends.

Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMED stock can currently be purchased for approximately $77.31.

Amedisys (NASDAQ:AMED) has a market capitalization of $2.52 billion and generates $2.22 billion in revenue each year. The health services provider earns $118.61 million in net income (profit) each year or $3.44 on an earnings per share basis.

The company employs 20,000 workers across the globe.

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The official website for the company is www.amedisys.com. The health services provider can be reached via phone at (225) 292-2031, via email at ir@amedisys.com, or via fax at 225-292-8163.